Abstracts Archive - Page 1106 of 2607 - ACR Meeting Abstracts

Abstract Number: 2489 • 2019 ACR/ARP Annual Meeting
Differences in Clinical Characteristics, Quality of Life, Disability, and Work Productivity in Psoriatic Arthritis Patients by Gender: Findings from a Cross-sectional Survey in the US and Europe
Laure Gossec¹, Jessica Walsh ², Kaleb Michaud ³, Steve Peterson ⁴, Elizabeth Holdsworth ⁵, Chetan Karyekar ⁴, Nicola Booth ⁶, Jessalyn Kemp ⁷, Soumya Chakravarty ⁸, Shelly Kafka ⁹ and Alexis Ogdie ¹⁰, ¹Sorbonne Université and Hôpital Pitié-Salpêtrière, Paris, France, ²Division of Rheumatology, University of Utah, Salt Lake City, UT, ³University of Nebraska Medical Center, Omaha, NE, ⁴Janssen Global Services, LLC, Horsham, PA, ⁵Adelphi Real World, Manchester, England, United Kingdom, ⁶Adelphi Real World, Bollington, United Kingdom, ⁷Adelphi Real World, Manchester, United Kingdom, ⁸Janssen Scientific Affairs, LLC; Drexel University College of Medicine, Horsham; Philadelphia, PA, ⁹Janssen Scientific Affairs, LLC, Horsham, PA, ¹⁰Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA
Background/Purpose: Psoriatic arthritis (PsA) prevalence is equal in men and women, though gender may play a role in driving mechanisms of PsA leading to differences…
Abstract Number: 2490 • 2019 ACR/ARP Annual Meeting
The Cutaneous Microbiome of Psoriatic Disease Is Influenced by Disease Susceptibility HLA Alleles but Not Clinical Phenotype
Meital Yerushalmi¹, Osvaldo Espin-Garcia ², Justine (Yang) Ye ³, Remy Pollock ⁴, Sara Rahmati ³, Lihi Eder ⁵, Mark Silverberg ⁶ and Vinod Chandran ⁷, ¹University of Toronto, University Health Network, Toronto, ON, Canada, ²Division of Biostatistics, Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada, ³University Health Network, University of Toronto, Toronto, ON, Canada, ⁴Krembil Research Institute, University Health Network, Toronto, Canada, ⁵Women’s College Hospital and the Department of Medicine, University of Toronto, Toronto, Canada, ⁶Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ⁷University Health Network, University of Toronto, Toronto, Canada
Background/Purpose: Psoriasis is an inflammatory skin disease. Psoriatic arthritis (PsA) is an inflammatory arthritis that affects 30% of psoriasis patients. The heterogeneity of psoriatic disease…
Abstract Number: 2491 • 2019 ACR/ARP Annual Meeting
Predictors of DAPSA28 Remission at 6 Months in Bio-Naive Patients with Psoriatic Arthritis Starting a TNF Inhibitor in Clinical Practice– Results from the EuroSpA Collaboration
Lykke Midtbøll Ørnbjerg¹, Stylianos Georgiadis ², Lennart Jacobsson ³, Anne Gitte Loft ⁴, Florenzo Iannone ⁵, Burkhard Moeller ⁶, Joe Sexton ⁷, Herman Mann ⁸, Maria José Santos ⁹, Manuel Pombo-Suarez ¹⁰, Kari K. Eklund ¹¹, Matija Tomsic ¹², Bjorn Gudbjornsson ¹³, Şükran Erten ¹⁴, Catalin Codreanu ¹⁵, Irene van der Horst-Bruinsma ¹⁶, Johan Wallman ¹⁷, Marco Sebastiani ¹⁸, Michael J. Nissen ¹⁹, Eirik Kristianslund ²⁰, Karel Pavelka ⁸, Elsa Vieira-Sousa ²¹, Carlos Sánchez-Piedra ²², Nina Trokovic ²³, Ziga Rotar ²⁴, Thorvardur J Love ²⁵, servet Yolbas ²⁶, Ruxandra IONESCU ²⁷, Marleen van de Sande ¹⁶, Gareth Jones ²⁸, Brigitte Michelsen ²⁹, Mikkel Østergaard ³⁰ and Merete Lund Hetland ¹, ¹DANBIO and Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre of Head and Orthopaedics, Rigshospitalet, Copenhagen, Denmark, ²DANBIO registry and Copenhagen Center for Arthritis Research, Centre for Rheumatology and Spine Diseases, Rigshospitalet, Copenhagen, Denmark, ³Dept of Rheumatology and Inflammation Research, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Sweden,, Gothenburg, Sweden, ⁴Department of Rheumatology, Aarhus University Hospital., Aarhus, Denmark, ⁵Department of Emergency and Transplantation , Rheumatology Unit, University Hospital of Bari, Bari, Italy., Bari, Italy, ⁶University Hospital Bern, Bern, Switzerland, ⁷Diakonhjemmet Hospital, Dept. of Rheumatology, Oslo, Norway, ⁸Institute of Rheumatology, Department of Rheumatology, 1st Faculty of Medicine, Prague, Czech Republic, Prague 2, Czech Republic, ⁹Rheumatology department, Hospital Garcia de Orta, Almada, Portugal, ¹⁰Unit Research, Spanish Society of Rheumatology, Madrid, Spain, ¹¹ROB-FIN registry, Department of Medicine, Helsinki University and University Hospital, Helsinki, Finland, ¹²Department of Rheumatology, University Medical Centre, Ljubjana, Slovenia, ¹³Centre for Rheumatology Research, Landspitali and Faculty of Medicine, University of Iceland, Reykjavik, Iceland, ¹⁴Yıldırım Beyazıt University, Ankara, Turkey, ¹⁵Center of Rheumatic Diseases, University of Medicine and Pharmacy, Bucharest, Romania., Bucharest, Romania, ¹⁶Amsterdam University Medical Center, Amsterdam, Netherlands, ¹⁷Department of Clinical Sciences Lund, Rheumatology Lund University, Lund, Sweden, ¹⁸Rheumatology Unit, Department of Surgery, Medicine, Dentistry and Morphological Sciences with Transplant Surgery, Oncology and Regenerative Medicine Relevance, Azienda Policlinico di Modena, University of Modena and Reggio Emilia, Modena, Italy, ¹⁹University Hospital Geneva, Geneva, Switzerland, ²⁰Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway., Oslo, Norway, ²¹Rheumatology and Metabolic Bone Diseases, Hospital de Santa Maria - Centro Hospitalar Lisboa Norte, EPE | Rheumatology Research Unit, Instituto de Medicina Molecular - Faculty of Medicine, University of Lisbon, Lisbon Academic Medical Centre, Lisbon, Portugal,, Lisbon, Portugal, ²²Research Unit, Spanish Society of Rheumatology, Madrid, Spain, ²³Helsinki University Central Hospital, Helsinki, Finland, ²⁴UMC LJUBLJANA, DPT. OF RHEUMATOLOGY, LJUBLJANA, Slovenia, ²⁵Faculty of Medicine, University of Iceland, Reykjavik, Iceland, ²⁶TURKBIO registry and Celal Bayar University School of Medicin, Division of Rheumatology, Malatya, Turkey, ²⁷SPITALUL CLINIC SFANTA MARIA, Bucharest, ²⁸University of Aberdeen, Aberdeen, United Kingdom, ²⁹EuroSpA Coordinating Center, Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre for Head and Orthopaedics, Rigshospitalet, Glostrup, Glostrup, Denmark, ³⁰Copenhagen Center for Arthritis Research, University of Copenhagen, Copenhagen, Denmark
Background/Purpose: Tumor necrosis factor inhibitors (TNFi) have contributed to improved prognosis in patients with psoriatic arthritis (PsA). However, many patients treated with TNFi fail to…
Abstract Number: 2492 • 2019 ACR/ARP Annual Meeting
Efficacy and Safety of Disease-Modifying Drugs in Psoriatic Arthritis (PsA): A Systematic Literature Review
Andreas Kerschbaumer¹, Josef Smolen ¹, Maxime Dougados ², Maarten de Wit ³, Jette Primdahl ⁴, Iain McInnes ⁵, Désirée van der Heijde ⁶, Louise Falzon ⁷, Xenofon Baraliakos ⁸ and Laure Gossec ⁹, ¹Medical University of Vienna, Vienna, Austria, ²Cochin Hospital, Paris, France, ³Department of Medical Humanities, Amsterdam Public Health (APH), Amsterdam University Medical Centre, Amsterdam, Netherlands, ⁴Dansk Gigthospital, Sønderborg, Denmark, ⁵Institute of Infection, Immunity & Inflammation, University of Glasgow, Glasgow, United Kingdom, ⁶Leiden University Medical Center, Leiden, Netherlands, ⁷Northwell Health, New York, ⁸Rheumazentrum Ruhrgebiet-Ruhr-University Bochum, Herne, Germany, Herne, Germany, ⁹Sorbonne Université and Hôpital Pitié-Salpêtrière, Paris, France
Background/Purpose: There is now an increasing range of drug options in PsA. To inform the update of the EULAR PsA management recommendations (Ref 1), we…
Abstract Number: 2493 • 2019 ACR/ARP Annual Meeting
IL-6 and TNF-α Influence on Clinical Manifestations, Activity and Comorbidity in Psoriatic Arthritis Patients
Maria Elisa Acosta¹, Luis Gomez-Lechon ¹, Guadalupe Manzano Canabal ¹, Olga Compan ², Cristina Hidalgo ³, Olga Martinez ¹, Ana Turrión ¹, Javier del Pino ¹ and Carlos Montilla ¹, ¹Hospital Clínico Universitario de Salamanca, Salamanca, Spain, ²Hospital Clinico Universitario de Salamanca, SALAMANCA, Spain, ³Hospital Clínico Universitario de Salamanca, Salamanca, Castilla y Leon, Spain
Background/Purpose: The activation of the Th-1 and Th-17 lymphocytes response seems to be one of the causes associated with PsA onset. During this process cytokines…
Abstract Number: 2494 • 2019 ACR/ARP Annual Meeting
Comparison of Comorbidity in Spondyloarthritis: Influence on Inflammatory Activity in Patients with Psoriatic Arthritis
Luis Gomez-Lechon¹, Maria Elisa Acosta ¹, Guadalupe Manzano Canabal ¹, Olga Compan ¹, Cristina Hidalgo ², Olga Martinez ¹, Ana Turrión ¹, Javier del Pino ¹ and Carlos Montilla ¹, ¹Hospital Clínico Universitario de Salamanca, Salamanca, Spain, ²Hospital Clínico Universitario de Salamanca, Salamanca, Castilla y Leon, Spain
Background/Purpose: Psoriatic arthritis (PsA) is a heterogeneous disease that is included in the group of spondyloarthritis. Although PsA has its own clinical characteristics, it has…
Abstract Number: 2495 • 2019 ACR/ARP Annual Meeting
Oligoarticular Psoriatic Arthritis
Dafna Gladman¹, Justine (Yang) Ye ², Vinod Chandran ³, Ker-Ai Lee ⁴ and Richard Cook ⁵, ¹Toronto Western Hospital, Toronto, Canada, Toronto, ON, Canada, ²University Health Network, University of Toronto, Toronto, ON, Canada, ³University Health Network, University of Toronto, Toronto, Canada, ⁴University of Waterloo, Waterloo, ⁵University of Waterloo, Waterloo, Canada
Background/Purpose: Oligoarthritis, defined as ≤4 affected joints, was recognized as a pattern of psoriatic arthritis (PsA) by Moll and Wright. In some jurisdictions, patients with…
Abstract Number: 2496 • 2019 ACR/ARP Annual Meeting
Serum Metabolomic Analysis of Psoriatic Arthritis Using Solid Phase Microextraction – Liquid Chromatography – High-Resolution Mass Spectrometry Identifies Putative Disease Activity Markers
Vinod Chandran¹, Nikita Looby ², Nathaly Reyes-Garces ², Rohan Machhar ³, Miao Yu ², Anna Roszkowska ², Janusz Pawliszyn ² and Vathany Kulasingam ⁴, ¹University Health Network, University of Toronto, Toronto, Canada, ²University of Waterloo, Waterloo, ON, Canada, ³Krembil Research Institute, University Health Network, Toronto, Canada, ⁴University of Toronto, Toronto, ON, Canada
Background/Purpose: Disease activity in psoriatic arthritis (PsA) is often difficult to assess but drives treatment decisions, joint damage and long-term outcomes. We aimed to identify…
Abstract Number: 2497 • 2019 ACR/ARP Annual Meeting
Description and Prevalence of Spondyloarthritis in Unselected Patients with Psoriasis, Acute Anterior Uveitis, and Inflammatory Bowel Disease Presenting with Undiagnosed Back Pain
Walter P. Maksymowych¹, Raj Carmona ², Jonathan Chan ³, James Yeung ⁴, Sibel Zehra Aydin ⁵, Liam Martin ⁶, Ariel Masetto ⁷, Dianne Mosher ⁸, Olga Ziouzina ⁶, Stephanie Keeling ⁹, Sherry Rohekar ¹⁰, Rana Dadashova ¹¹, Joel Paschke ¹¹, Amanda Carapellucci ¹¹ and Robert Lambert ¹², ¹University of Alberta/CARE ARTHRITIS, Edmonton, AB, Canada, ²McMaster University, Hamilton, Canada, ³Artus Health Clinic, Vancouver, BC, Canada, ⁴Yeung Rheumatology, Vancouver, Canada, ⁵University of Ottawa Faculty of Medicine, Rheumatology,Ottawa Hospital Research Institute, 1967 Riverside Drive, Ottawa, ON, K1H 7W9, CANADA, Ottawa, Canada, ⁶University of Calgary, Calgary, Canada, ⁷Université de Sherbrooke, Sherbrooke, QC, Canada, ⁸University of Calgary, Calgary, AB, Canada, ⁹University of Alberta, Edmonton, AB, Canada, ¹⁰Western University, London, ON, Canada, ¹¹CARE Arthritis, Edmonton, Canada, ¹²University of Alberta, Edmonton, Canada
Background/Purpose: There is limited prospective data as to the frequency of axial spondyloarthritis (axSpA) in unselected patients referred to rheumatologists with undiagnosed back pain who…
Abstract Number: 2498 • 2019 ACR/ARP Annual Meeting
Incidence and Predictors of Heart Failure in Patients with Psoriatic Disease – a Cohort Study
Sahil Koppikar¹, Keith Colaco ², Paula Harvey ³, Vinod Chandran ⁴, Dafna Gladman ⁵, Richard Cook ⁶ and Lihi Eder ⁷, ¹University of Toronto, Markham, ON, Canada, ²University of Toronto, Women's College Hospital, University Health Network, Toronto, ON, Canada, ³Women's College Hospital, Toronto, ON, Canada, ⁴University Health Network, University of Toronto, Toronto, Canada, ⁵Toronto Western Hospital, Toronto, Canada, Toronto, ON, Canada, ⁶University of Waterloo, Waterloo, Canada, ⁷Women’s College Hospital and the Department of Medicine, University of Toronto, Toronto, Canada
Background/Purpose: Data about heart failure (HF) in patients with psoriatic disease (PsD) are sparse. The aims of the study were to: 1) determine the incidence…
Abstract Number: 2499 • 2019 ACR/ARP Annual Meeting
Predicting Risk of Developing Psoriatic Arthritis (PsA) in Siblings of Patients with Psoriatic Arthritis
Winifred Badaiki¹, Quan Li ², Tanya Burry ¹, Fiona Landells ¹, Rachel Gehue ¹, Cindy Penney ³, DIanne Codner ¹, Amanda Dohey ¹, Kerri Smith ¹, Fatima Abji ⁴, Dafna Gladman ⁵, Darren O'Rielly ¹, Vinod Chandran ⁶ and Proton Rahman ⁷, ¹Memorial University, St. Johns, Canada, ²Toronto Western Hospital, Toronto, Canada, ³Memorial University, St Johns, Canada, ⁴Memorial University, Toronto, Canada, ⁵Toronto Western Hospital, Toronto, Canada, Toronto, ON, Canada, ⁶University Health Network, University of Toronto, Toronto, Canada, ⁷Memorial University, St. Johns, NL, Canada
Background/Purpose: Delay in diagnosis of psoriatic arthritis (PsA) has been shown to contribute to poor radiographic and functional outcome and less successful response to treatment…
Abstract Number: 2500 • 2019 ACR/ARP Annual Meeting
Current Smoking Status Increases the Risk of Axial Psoriatic Arthritis: An Explanation to Smoking Paradox
Dilek Solmaz ¹, Umut Kalyoncu ², Ilaria Tinazzi ³, Sibel Bakirci ⁴, Ozun Bayindir ⁵, Atalay Dogru ⁶, Ediz Dalkılıç ⁷, Gezmiş Kimyon ⁸, Cem Ozisler ⁹, Gozde Cetin ¹⁰, Levent Kilic ¹¹, Ahmet Omma ¹², Meryem Can ¹³, Sema Yılmaz ¹⁴, Abdulsamet Erden ¹⁵ and Sibel Zehra Aydin¹⁶, ¹Izmir Katip Celebi University, Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, İzmir, Turkey, ²Hacettepe University Department of Rheumatology, Ankara, Turkey, ³Sacro Cuore Don Calabria Hospital, Unit of Rheumatology, Verona, Italy, ⁴Antalya Education and Research Hospital, Antalya, Turkey, ⁵Ege University, Department of Internal Medicine, Division of Rheumatology, Izmir, Turkey, ⁶Suleyman Demirel University, Department of Internal Medicine, Division of Rheumatology, Isparta, Turkey, ⁷Uludağ University, Bursa, Turkey, ⁸Mustafa Kemal University, Hatay, Turkey, ⁹Diskapi Yildirim Beyazit Education and Research Hospital, Department of Internal Medicine, Division of Rheumatology, Ankara, ¹⁰Kahramanmaras Sutcu Imam University, Department of Internal Medicine, Division of Rheumatology, Kahramanmaras, ¹¹Hacettepe University, Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Ankara, Turkey, ¹²Ankara Numune Education and Research Hospital, Department of Internal Medicine, Division of Rheumatology, Ankara, Turkey, ¹³Marmara University, Division of Rheumatology, Istanbul, Turkey, Istanbul, Turkey, ¹⁴Division of Rheumatology, Selcuk University School of Medicine, Konya, Turkey, Konya, Turkey, ¹⁵Hacettepe University, Ankara, Turkey, ¹⁶University of Ottawa Faculty of Medicine, Rheumatology,Ottawa Hospital Research Institute, 1967 Riverside Drive, Ottawa, ON, K1H 7W9, CANADA, Ottawa, Canada
Background/Purpose: Smoking has been shown to be associated with an increased risk of psoriatic arthritis (PsA) in the general population, but there are controversies among patients…
Abstract Number: 2501 • 2019 ACR/ARP Annual Meeting
The Association Between Metabolic Syndrome and Radiographic Damage in Psoriatic Arthritis
Sevket Tunc¹, Justine (Yang) Ye ², Dafna Gladman ³ and Vinod Chandran ¹, ¹University Health Network, University of Toronto, Toronto, Canada, ²University Health Network, University of Toronto, Toronto, ON, Canada, ³Toronto Western Hospital, Toronto, Canada, Toronto, ON, Canada
Background/Purpose: Psoriatic Arthritis (PsA) is associated with a higher prevalence of metabolic syndrome (MetS). MetS itself is also associated with a state of chronic, low-grade…
Abstract Number: 2502 • 2019 ACR/ARP Annual Meeting
Normalization of Inflammatory Gene Expression and Cellular Markers by Abatacept in the Skin Lesions of Psoriatic Arthritis Patients: A Biopsy Substudy of a Phase III Study
Jennifer Belasco¹, Sandra Garcet ¹, Mustimbo roberts ², Judilyn Fuentes-Duculan ¹, Norma Kunjravia ¹, Inna Cueto ¹, Israel Coats ¹, Xuan Li ¹, Philip Mease ³, Alice Gottlieb ⁴, Oliver FitzGerald ⁵ and James Krueger ¹, ¹The Rockefeller University, New York, NY, ²Bristol-Myers Squibb, Princeton, NJ, ³Swedish Medical Center/Providence St Joseph Health, and University of Washington, Seattle, WA, ⁴Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY, USA, New York City, NY, ⁵University College Dublin, Dublin, Ireland
Background/Purpose: Abatacept (ABA), a selective T-cell co-stimulation modulator, has been shown to improve disease activity in patients with psoriatic arthritis (PsA), but its effect on…
Abstract Number: 2503 • 2019 ACR/ARP Annual Meeting
Achilles Tendon Enthesitis and Disease Burden in Psoriatic Arthritis and Axial Spondyloarthritis: Baseline Results from a Randomized Controlled Trial
Frank Behrens¹, Philipp Sewerin ², Eugenio de Miguel ³, Yusuf Patel ⁴, Anastas Batalov ⁵, Eva Dokoupilova ⁶, Christine Kleinmond ⁷, Effie Pournara ⁸, Ankita Shekhawat ⁹, Claudia Jentzsch ¹⁰, Annette Wiedon ¹⁰ and Xenofon Baraliakos ¹¹, ¹CIRI/Rheumatology and Fraunhofer TMP, Goethe-University, Frankfurt, Germany, ²Department of Rheumatology & Hiller Research Unit, University Hospital Düsseldorf,, Duesseldorf, Germany, ³Rheumatology Department, Hospital Universitario La Paz, Madrid, Spain, ⁴Hull University Teaching Hospitals, Hull, United Kingdom, ⁵Medical University of Plovdiv, University Hospital Kaspela, Plovdiv, Bulgaria, ⁶MEDICAL PLUS s.r.o., Uherske Hradiste, University of Veterinary and Pharmaceutical sciences, Faculty of Pharmacy, Department of Pharmaceutics, Uherské Hradiště, Czech Republic, ⁷ClinProject GmbH, Eurasburg, Germany, ⁸Novartis Pharma AG, Basel, Basel-Stadt, Switzerland, ⁹Novartis Healthcare Pvt. Ltd., Hyderabad, India, ¹⁰Novartis Pharma GmbH, Nürnberg, Germany, ¹¹Rheumazentrum Ruhrgebiet-Ruhr-University Bochum, Herne, Germany, Herne, Germany
Background/Purpose: Enthesitis is a common feature of Spondyloarthritis (SpA)1. Enthesitis at the Achilles tendon is an important manifestation with impact on function which is often…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].